Alzheimer’s disease and sleep disorders: Insights into the possible disease connections and the potential therapeutic targets

Marde, Vaibhav S.; Atkare, Utkarsha A.; Gawali, Shweta V.; Tiwari, Pramil; Badole, Saurabh P.; Wankhede, Nitu L.; Taksande, Brijesh G.; Upaganlawar, Aman; Umekar, Milind J.; Kale, Mayur B.

doi:10.1016/j.ajp.2021.102961

Cited by 16 publications

(3 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemical structures of melatonin and valerenic acid Currently, studies with valerian focused on treating anxiety and insomnia continue to advance with very positive results (Das et al, 2021;Borrás et al, 2021). Also, in trials in patients with neuropathies (Soltani et al, 2021), mental disorders such as Alzheimer's (Marde et al, 2022), and in pregnancy (Kennedy et al, 2013), the beneficial effects of valerian extracts, as well as other phytotherapeutics, have been proven with interesting results. Another attractive line of research with valerian is the studies against skeletal muscle atrophy, of great interest in athletes (Kim et al, 2022).…”

Section: Resultsmentioning

confidence: 99%

Phytomelatonin content in Valeriana officinalis L. and some related phytotherapeutic supplements

LOSADA¹,

Caño²,

Hernández‐Ruíz³

et al. 2022

International Journal of Plant Based Pharmaceuticals

View full text Add to dashboard Cite

The use of medicinal plants as an alternative phytotherapeutic remedy against mild illnesses and dysfunctions is increasingly embraced by people. Among these dysfunctions, episodes of nervousness and anxiety due to lack of sleep and insomnia are becoming more and more frequent among the population. To remedy these problems, several plants with sedative activity are recommended. In particular, valerian root (Valeriana officinalis L.) is the most recommended and studied with a significant difference. This study presented a quantification of the phytomelatonin contents in valerian root and several related and recommended herb supplements against nervousness, anxiety, and insomnia. The results showed the presence of phytomelatonin in all the samples analyzed. The high phytomelatonin contents in valerian root and its supplements indicated that, in addition to the known constituents of valerian root such as valerenic acid, phytomelatonin also contributed to the phytotherapeutic activity of this plant since the relaxing and sleep-inducing activity of melatonin is well documented. The recommended daily doses of valerian are analyzed according to their phytomelatonin content, and recommendations are given on the possible synergistic action of the components of valerian as a relaxant and sleep inducer in patients with these dysfunctions. It is also recommended to document the phytomelatonin contents in phytotherapeutic preparations.

show abstract

Section: Resultsmentioning

confidence: 99%

Phytomelatonin content in Valeriana officinalis L. and some related phytotherapeutic supplements

LOSADA¹,

Caño²,

Hernández‐Ruíz³

et al. 2022

International Journal of Plant Based Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Disrupted nocturnal sleep, circadian rhythm, and excessive daytime sleepiness are the core components of AD. Severe sleep disturbances are considered to be the result of damage to the neuronal pathways in patients with late-stage AD [57], as degenerative changes have been detected in sleep/wake regulatory areas such as cortical and hippocampal neurons, cortical presynaptic cholinergic nerve endings, pons, and medulla reticular formations [58]. More significantly, the sensitive areas affected by Alzheimer's disease overlap with the brain structures affected by sleep disorders [59].…”

Section: Obstructive Sleep Apnea In Alzheimer's Diseasementioning

confidence: 99%

Respiratory Dysfunction in Alzheimer’s Disease—Consequence or Underlying Cause? Applying Animal Models to the Study of Respiratory Malfunctions

Wrzesień,

Andrzejewski,

Jampolska

et al. 2024

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative brain disease that is the most common cause of dementia among the elderly. In addition to dementia, which is the loss of cognitive function, including thinking, remembering, and reasoning, and behavioral abilities, AD patients also experience respiratory disturbances. The most common respiratory problems observed in AD patients are pneumonia, shortness of breath, respiratory muscle weakness, and obstructive sleep apnea (OSA). The latter is considered an outcome of Alzheimer’s disease and is suggested to be a causative factor. While this narrative review addresses the bidirectional relationship between obstructive sleep apnea and Alzheimer’s disease and reports on existing studies describing the most common respiratory disorders found in patients with Alzheimer’s disease, its main purpose is to review all currently available studies using animal models of Alzheimer’s disease to study respiratory impairments. These studies on animal models of AD are few in number but are crucial for establishing mechanisms, causation, implementing potential therapies for respiratory disorders, and ultimately applying these findings to clinical practice. This review summarizes what is already known in the context of research on respiratory disorders in animal models, while pointing out directions for future research.

show abstract

“…169 Sleep disorders implicated in AD include SDB, insomnia, RBD, RLS, and EDS. 170 171 In addition to these sleep disorders, AD is associated with alterations to sleep–wake rhythm regulation beyond the changes seen in normal aging, including difficulty falling asleep, repeated nighttime arousal and awakening, altered sleep architecture, decreased sleep duration, daytime sleepiness, and sundowning. 170 There appears to be a bidirectional relationship between AD and sleep disturbance, such that disrupted sleep precedes, progresses, and is progressed by AD.…”

Section: Alzheimer's Diseasementioning

confidence: 99%

Sleep Disturbances in Neurological Disease: A Target for Intervention

Khambadkone

Benjamin

2022

Semin Neurol

View full text Add to dashboard Cite

Sleep is a biological function required for neurological and general health, but a significant and under-recognized proportion of the population has disturbed sleep. Here, we briefly overview the biology of sleep, sleep requirements over the lifespan, and common sleep disorders. We then turn our attention to five neurological diseases that significantly contribute to global disease burden and neurology practice makeup: epilepsy, headache, ischemic stroke, Parkinson's disease, and Alzheimer's disease. For each disease, we review evidence that sleep disturbances contribute to disease risk and severity and discuss existing data that addressing sleep disturbances may have disease-modifying effects. We provide recommendations derived from the literature and existing clinical guidelines to facilitate the evaluation and management of sleep disturbances within the context of each neurological disease. Finally, we synthesize identified needs and commonalities into future directions for the field and practical sleep-related recommendations for physicians caring for patients at risk for or currently suffering from neurological disease.

show abstract

Alzheimer’s disease and sleep disorders: Insights into the possible disease connections and the potential therapeutic targets

Cited by 16 publications

References 95 publications

Phytomelatonin content in Valeriana officinalis L. and some related phytotherapeutic supplements

Phytomelatonin content in Valeriana officinalis L. and some related phytotherapeutic supplements

Respiratory Dysfunction in Alzheimer’s Disease—Consequence or Underlying Cause? Applying Animal Models to the Study of Respiratory Malfunctions

Sleep Disturbances in Neurological Disease: A Target for Intervention

Contact Info

Product

Resources

About